Polycystic Ovarian Syndrome - Drug Pipeline Landscape, 2023

Polycystic Ovarian Syndrome - Drug Pipeline Landscape, 2023

Polycystic Ovarian Syndrome (PCOS) is a metabolic disorder which causes hormonal imbalance in women and tends to increase level of male hormones leads to erratic menstrual cycles, missed periods and irregular ovulation, abnormal hair growth on the body and face simultaneously it can lead to heart disease and diabetes in long term. Small cysts may develop on the ovaries (fluid-filled sacs) due to lack of ovulation (anovulation). However, despite the name "polycystic," one does not need to have cysts on ovaries to have PCOS.

The most common causes of Polycystic Ovarian Syndrome are genetics, higher male hormone (androgen) levels, insulin resistance, low-grade inflammation, obesity.

The most common symptoms of Polycystic Ovarian Syndrome include irregular periods or no periods, heavy menstrual bleeding, difficulty getting pregnant, excessive hair growth on the face, chest, back or buttocks, hair loss, acne.

Polycystic Ovarian Syndrome can be diagnosed by the doctors by discussion of your symptoms, menstrual periods and any weight changes and physical pelvic exam including blood tests and ultrasound/imaging tests.

The most common treatments for Polycystic Ovarian Syndrome are medications such as combination birth control pills, progestin therapy, or Clomiphene, Letrozole, Gonadotropins, lifestyle changes such as change in diet and activity.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Polycystic ovarian syndrome treatment such as Corifollitropin Alfa, Elagolix, Saroglitazar and others. Key players involved in the development of therapies to treat polycystic ovarian syndrome are Merck Sharp & Dohme LLC, AbbVie, Zydus Lifesciences Ltd, Spruce Biosciences, PT. Prodia Stem Cell Indonesia and others. One drug is under late-stage Phase III clinical trials, four drugs are in Phase II clinical trials and some other drugs are under preclinical stages of development.

Report Highlights

Global Insight Service's, Polycystic Ovarian Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Polycystic Ovarian Syndrome pipeline drugs. This report covers detailed insights on Polycystic Ovarian Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Polycystic Ovarian Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.